Insmed Incorporated (NASDAQ:INSM) reported its Q3 results last week, with disappointing revenues providing more evidence of the continuous slowdown due to the delta variant. ARIKAYCE Q3 revenue, primarily impacted by the regional variability of the delta variant, was 4% and 9% shy of consensus estimates. R&D spending was higher due to the ongoing clinical studies.

Analysts at Berenberg Bank believe that the performance has been overall positive despite pandemic-related headwinds. The analysts remain positive on the long-term growth prospects for Insmed, anticipating a recovery in Q4 and beyond.